Erratum: Comparison of the two most commonly used treatments for pyoderma gangrenosum: Results of the STOP GAP randomised controlled trial (BMJ (Online) (2015) 350 (h2958) DOI: 10.1136/bmj.h2958);Comparison of the two most commonly used treatments for pyoderma gangrenosum: Results of the STOP GAP randomised controlled trial

The BMJ

Volumn 350, Issue , 2015, Pages

  Ormerod, Anthony D ^a   Thomas, Kim S ^b   Craig, Fiona E ^c   Mitchell, Eleanor ^b   Greenlaw, Nicola ^d   Norrie, John ^a   Mason, James M ^e   Walton, Shernaz ^f   Johnston, Graham A ^g   Williams, Hywel C ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e DURHAM UNIVERSITY   (United Kingdom)

^f HULL ROYAL INFIRMARY   (United Kingdom)

^g LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PREDNISOLONE; CYCLOSPORIN; DERMATOLOGICAL AGENT;

ADULT; ADVERSE DRUG REACTION; ANEMIA; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; CANDIDIASIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; EDEMA; ENDOCRINE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; INFECTION; INFLAMMATION; KIDNEY DISEASE; LEUKOCYTOSIS; LIVER DYSFUNCTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARESTHESIA; PATIENT PREFERENCE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SELF REPORT; SKIN DISEASE; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; ULCER HEALING; UNITED KINGDOM; URINARY TRACT DISEASE; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VARICOSE ULCER; WOUND HEALING;

CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PREDNISOLONE; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VARICOSE ULCER; WOUND HEALING;

EID: 84936770257     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j1462     Document Type: Erratum

References (26)

1. Langan SM, Groves RW, Card TR, et al. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 2012;132:2166-70.
2. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;333:181-4.
3. Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011;165:1244-50.
4. Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004;43:790-800.
5. Tremezaygues L, Schmaltz R, Vogt T, et al. [Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy]. Hautarzt 2010;61:345-53; quiz 54-5.
6. Zuo KJ, Fung E, Tredget EE, et al. A systematic review of post-surgical pyoderma gangrenosum: Identification of risk factors and proposed management strategy. J Plast Reconstr Aesthet Surg 2015;68:295-303.
7. Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010;62:646-54.
8. British Association of Dermatologists. Patient Information Leaflet on pyoderma gangrenosum. 2013. www.bad.org.uk/for-the-public/patient-information-leaflets/pyoderma-gangrenosum.
9. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006;55:505-9.
10. Reichrath J, Bens G, Bonowitz A, et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-83.
11. Craig FF, Thomas KS, Mitchell EJ, et al. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 2012;13:51.
12. RALLOC: Stata module to design randomized controlled trials [program]. Boston College Department of Economics, 1997.
13. Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol 2000;142:960-4.
14. Cardinal M, Phillips T, Eisenbud DE, et al. Nonlinear modeling of venous leg ulcer healing rates. BMC Dermatol 2009;9:2.
15. Foss CE, Clark AR, Inabinet R, et al. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2008;22:943-9.
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
17. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41.
18. Brooks R. EuroQol - the current state of play. Health Policy 1996;37:53-72.
19. Matis WL, Ellis CN, Griffiths CE, et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992;128:1060-4.
20. Elgart G, Stover P, Larson K, et al. Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients. J Am Acad Dermatol 1991;24:83-6.
21. Vidal D, Puig L, Gilaberte M, et al. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatolog Treat 2004;15:146-52.
22. Capella GL, Frigerio E, Fracchiolla C, et al. The simultaneous treatment of inflammatory bowel diseases and associated pyoderma gangrenosum with oral cyclosporin A. Scand J Gastroenterol 1999;34:220-1.
23. Friedman S, Marion JF, Scherl E, et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001;7:1-7.
24. Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013;38:563-72.
25. Arguelles-Arias F, Castro-Laria L, Lobaton T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 2013;58:2949-54.
26. Layfield C, Yong A, Thomas KS, et al. The UK Dermatology Clinical Trials Network-how far have we come? Clin Investig 2014;4:209-14.